Blood Banking Market by Blood Component Type, Testing Type, Donor Type, Collection Method, Application, End User

List of Tables

The Blood Banking Market is projected to grow by USD 35.38 billion at a CAGR of 8.58% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 19.87 billion
Estimated Year [2026]	USD 21.55 billion
Forecast Year [2032]	USD 35.38 billion
CAGR (%)	8.58%

Blood banking is a mission-critical healthcare infrastructure segment that supports surgery, trauma care, oncology, obstetrics, hematology, transplant medicine, and disaster response. The World Health Organization reports approximately 118.5 million blood donations globally, with high-income countries collecting about 40% of donations despite representing roughly 16% of the global population, underscoring persistent access and utilization gaps.

For industry leaders, the blood banking market is shaped by safe blood collection, component processing, infectious disease testing, cold-chain logistics, inventory optimization, and regulatory compliance. Demand remains resilient because red blood cells, platelets, plasma, and specialized blood products are essential, time-sensitive therapies with limited substitutes.

Transformative Shifts in the Blood Banking Landscape

The blood banking landscape is shifting from volume-based collection toward precision supply management, traceability, and outcome-linked transfusion practices. Hospitals and blood centers are increasing reliance on leukoreduction, nucleic acid testing, pathogen reduction technologies, automated component processing, and digital donor engagement to improve safety, availability, and donor retention.

Regulatory expectations are also rising. Quality management systems, hemovigilance, donor screening, biologics compliance, and electronic records are becoming central to operational resilience as health systems face aging populations, variable donor participation, extreme weather disruptions, and growing need for rare blood types and platelet availability.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across blood banking by improving donor targeting, appointment scheduling, inventory forecasting, demand prediction, compatibility support, and transport routing. When validated against historical transfusion, expiry, and hospital utilization data, AI can help reduce wastage and strengthen matching between collection plans and clinical need.

The highest-value applications are decision-support tools rather than fully autonomous systems. Responsible deployment requires audited datasets, bias monitoring, cybersecurity controls, clinical validation, regulatory documentation, and human oversight because blood products are biologics used in high-risk care environments.

Key Regional Insights: Blood Banking Demand and Infrastructure

North America and Europe remain advanced blood banking regions due to mature hospital networks, strong hemovigilance, established regulatory and professional frameworks, and broad adoption of automated testing, component processing, and electronic traceability. North America emphasizes resilience after recurring supply shortages and weather-related disruptions, while Europe benefits from cross-border quality alignment, national transfusion services, and regionwide safety requirements for blood and blood components.

Asia-Pacific is expanding blood banking capability as China, India, Japan, Australia, and South Korea invest in hospital capacity, voluntary donation systems, digital health infrastructure, and advanced infectious disease testing. Latin America continues strengthening national coordination, with Brazil and Mexico acting as major demand centers for transfusion services across public and private healthcare settings. The Middle East, led by GCC health investment, is modernizing centralized blood services, high-acuity hospital capacity, and emergency preparedness, while Africa remains focused on improving voluntary donation rates, screening coverage, cold-chain reach, and equitable access to safe blood.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are advancing blood safety through regional health cooperation, donor education, quality system upgrades, and laboratory modernization, although infrastructure maturity varies widely across member states. The GCC is prioritizing centralized blood services, digital health integration, high-acuity care capacity, and emergency response readiness. The European Union benefits from harmonized quality, safety, traceability, and vigilance expectations for blood and blood components, supporting consistent transfusion standards across member countries.

BRICS countries represent a major growth base for blood banking because of population scale, urban hospital expansion, surgical volumes, cancer care development, and rising transfusion demand in Brazil, Russia, India, China, and South Africa. G7 countries lead in automation, quality systems, rare blood programs, patient blood management, and advanced testing adoption. NATO members increasingly view blood supply continuity as part of emergency preparedness, disaster response, military-civilian health resilience, and strategic medical logistics.

Key Country Insights: Major Blood Banking Markets

The United States and Canada have mature voluntary donation systems, sophisticated infectious disease testing, strong hospital transfusion governance, and established hemovigilance practices, while Mexico and Brazil are expanding modernization across collection networks, laboratory capacity, and public-private healthcare delivery. In Europe, the United Kingdom, Germany, France, Italy, and Spain operate high-standard blood systems supported by national quality frameworks, component therapy, donor screening, and patient blood management, while Russia maintains large-scale national capacity with regional variability in access and infrastructure.

China and India are high-priority blood banking markets because of population size, surgical demand, cancer care expansion, maternal health needs, and ongoing efforts to increase voluntary non-remunerated donation. Japan, Australia, and South Korea demonstrate advanced quality systems, automation, hemovigilance, and aging-population demand patterns, making them important benchmarks for safe, technology-enabled blood banking and hospital transfusion management.

Actionable Recommendations for Industry Leaders

Industry leaders should invest in interoperable blood management platforms that connect donor recruitment, appointment scheduling, laboratory testing, inventory, hospital ordering, transfusion records, and hemovigilance data. Forecasting models should be paired with clinician-led patient blood management programs to reduce avoidable transfusions while protecting availability for trauma, oncology, obstetrics, hematology, and emergency care.

Strategic priorities include diversifying donor pools, expanding rare blood registries, strengthening platelet logistics, improving cold-chain visibility, validating AI tools, and building redundancy in reagents, consumables, and transport capacity. Partnerships with hospitals, regulators, emergency agencies, donor organizations, and community groups are essential for improving resilience, equity, and public trust.

Research Methodology

This executive summary is based on triangulation of publicly available and industry-recognized sources, including the World Health Organization, national blood authorities, FDA and European regulatory guidance, AABB and ISBT standards, peer-reviewed transfusion medicine literature, hospital utilization trends, and health infrastructure indicators.

The methodology emphasizes verified secondary research, regulatory review, market signal analysis, and cross-validation across regional, group, and country-level healthcare data. Insights are framed to support executive decision-making without relying on unverified market estimates, market sizing, market share assumptions, or unsupported projections.

Conclusion

Blood banking is evolving from a collection-centered service into a digitally enabled, quality-driven healthcare infrastructure market. Safety, availability, traceability, and resilience are now defining operational and public health priorities across mature and emerging systems.

Organizations that combine validated automation, responsible AI, regulatory excellence, donor trust, equitable access strategies, and clinically aligned inventory management will be best positioned to improve access, reduce wastage, and support the rising global need for safe blood and blood components.

Product Code: MRR-434CCDA04D00

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Blood Banking Market, by Blood Component Type

7.1. Cryoprecipitate
7.2. Plasma
7.3. Platelets
7.4. Red Blood Cells
7.5. Whole Blood

8. Blood Banking Market, by Testing Type

8.1. Blood Grouping Testing
8.2. Infectious Disease Testing

9. Blood Banking Market, by Donor Type

9.1. Family Replacement Donor
9.2. Paid Donor
9.3. Voluntary Donor

10. Blood Banking Market, by Collection Method

10.1. Whole Blood Collection
10.2. Apheresis Collection
- 10.2.1. Plateletpheresis
- 10.2.2. Plasmapheresis
- 10.2.3. Leukapheresis

11. Blood Banking Market, by Application

11.1. Diagnostics
11.2. Research
11.3. Transfusion

12. Blood Banking Market, by End User

12.1. Ambulatory Surgical Centers
12.2. Blood Banks
12.3. Hospitals And Clinics

13. Blood Banking Market, by Region

13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa

14. Blood Banking Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Blood Banking Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. Competitive Landscape

16.1. Market Concentration Analysis, 2025
- 16.1.1. Concentration Ratio (CR)
- 16.1.2. Herfindahl Hirschman Index (HHI)
16.2. Recent Developments & Impact Analysis, 2025
16.3. Product Portfolio Analysis, 2025
16.4. Benchmarking Analysis, 2025

17. Company Profiles

17.1. Abbott Laboratories
17.2. Arctiko A/S
17.3. BAG Diagnostics GmbH
17.4. Baxter International Inc.
17.5. Beckman Coulter, Inc.
17.6. Becton Dickinson and Company
17.7. Bio-Rad Laboratories, Inc.
17.8. Cardinal Health, Inc.
17.9. Cerus Corporation
17.10. F. Hoffmann-La Roche Ltd.
17.11. Fresenius Kabi AG
17.12. Grifols S.A.
17.13. Haemonetics Corporation
17.14. Helmer Scientific, Inc.
17.15. ICU Medical, Inc.
17.16. Immucor, Inc.
17.17. JMS Transfusion Technology CO., LTD.
17.18. Labcold Ltd.
17.19. Macopharma SA
17.20. Nipro Corporation
17.21. QuidelOrtho Corporation
17.22. Sarstedt AG & Co. KG
17.23. Siemens Healthineers AG
17.24. Span Healthcare Private Limited
17.25. Terumo BCT, Inc.
17.26. Thermo Fisher Scientific Inc.
17.27. Tulip Diagnostics (P) Ltd.
17.28. WellSky Corporation